Format

Send to

Choose Destination
J Cosmet Dermatol. 2011 Sep;10(3):217-23. doi: 10.1111/j.1473-2165.2011.00569.x.

Facial skin-lightening benefits of the tetrapeptide Pro-Lys-Glu-Lys on subjects with skin types V-VI living in South Africa.

Author information

1
Evonik Goldschmidt GmbH, Essen, Germany. mike.farwick@evonik.com

Abstract

BACKGROUND:

Irregular skin pigmentation may be a substantial contributor to the signs of aging and to a person's lack of psychological well-being. Although a large number of skin-lightening agents are available, the opportunity exists to identify more efficacious agents, agents that target alternative biological mechanisms.

AIMS:

To provide clinical evidence of the skin-lightening effect of the tetrapeptide, Pro-Lys-Glu-Lys (PKEK), on subjects with skin types V-VI living in South Africa.

METHODS:

Pro-Lys-Glu-Lys was evaluated in a double-blind and vehicle-controlled clinical study using expert grading of digital images by comparing its effects in subjects with skin types V-VI suffering from facial melasma and postinflammatory hyperpigmentation.

RESULTS:

This study demonstrated the efficacy of PKEK on subjects with skin types V-VI. On comparing the two treatments, the skin-lightening peptide-containing formulation was significantly superior to the vehicle at 12 weeks on overall appearance (P < 0.05) and evenness of skin tone (P < 0.01).

CONCLUSIONS:

The tetrapeptide, PKEK, has proven skin-lightening benefits on skin discoloration from melasma and postinflammatory hyperpigmentation. These studies have been conducted on subjects with skin types V-VI living in South Africa, but we believe this technology to be suitable for all racial groups.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center